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Floating is a drug delivery system using polymer as matrix to control drug release. 
Chitosan has function as matrix polymer. This research aims at finding the optimum 
concentrations of chitosan on ranitidine HCl tablet. The granules was made into 6 
formulas with different concentrations of chitosan (16.00%, 16.50%, 17.00%, 17.50%, 
18.00%, 18.50%). The granules had been molded into a tablet and then evaluated. The 
dissolution test results from formula 4 and formula 5 are 120.19% and 99.45%. The 
statistical analysis of one-way ANOVA with 95% confidence level showed that there 
was no significant difference between the formulas 4 and 5. The conclussion that the 
optimization of the chitosan concentration as polymer matrix can increase the drug 
release of ranitidine HCl floating tablet. 
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ABSTRAK 
 
Sistem penghantaran obat secara floating adalah suatu cara yang dapat memperlama 
waktu kerja obat di dalam lambung. Dalam sistem floating, polimer digunakan untuk 
membentuk matriks yang memiliki kemampuan untuk mempertahankan pelepasan 
obat. Kitosan mempunyai fungsi sebagai matriks polimer karena dapat meningkatkan 
pelepasan tablet floating ranitidin HCl. Pada penelitian ini, kitosan diaplikasikan 
menjadi sediaan tablet floating yang bertujuan untuk mencari konsentrasi optimum 
kitosan pada tablet ranitidin HCl. Granul dibuat menjadi 6 formula dengan konsentrasi 
kitosan yang berbeda (16,00%, 16,50%, 17,00%, 17,50%, 18,00%, 18,50%). Tablet 
kemudian dievaluasi yaitu uji organoleptik, keseragaman bobot, keseragaman ukuran, 
kekerasan, kerapuhan, swelling, floating, menentukan panjang gelombang, membuat 
kurva kalibrasi, dan uji disolusi. Hasil uji disolusi yang diperoleh dari formula 4 dan 
formula 5 pada menit ke 480 yaitu 120,19% dan 99,45%. Dari analisa statistik ANAVA 
satu arah dengan taraf kepercayaan 95% menunjukkan bahwa tidak ada perbedaan 
bermakna antara formula 4 dan 5. Disimpulkan bahwa optimasi konsentrasi kitosan 
sebagai matriks polimer dapat meningkatkan pelepasan tablet ranitidin HCl. 






Ranitidine HCl is an H2-receptor antagonist that inhibits the action of histamine 
which competitively on H2 receptor. H2 receptor antagonists completely inhibit the 
secretion of gastric acid secretion induced by histamine and gastrin, but partially inhibit 
the secretion of gastric acid secretion induced by acetylcholine (Pediatri, 2002). 
Ranitidine HCl is used for gastric ulcer disease. Ranitidine HCl has a half life 2-3 hours, 
so it can be absorbed quickly and completely in the stomach (Tjay and Rahardja 2007). 
Ranitidine HCl is one of the drugs potentially to be formulated in floating tablet form. 
Ranitidine HCl is one of the drugs potentially to be formulated in tablet form floating. 
Floating tablets have the ability to swell then float and stay in the stomach for some 
time so that the drug can release slowly (Chawla et al. 2003). 
Floating system are required to use the polymer to form a matrix that has the 
ability to maintain the drug release. Chitosan is a biopolymer that can form a gel layer 
so it can control the release of active substances and have resistance in inhibiting 
excessive erosion of the floating tablet (Tarirai 2005). This gel layer serves as a barrier 
in around a matrix that controls drug release from the matrix (Satpathy 2008). 
In this research, optimization of chitosan was evaluated in variation 
concentration (16.00%, 16.50%, 17.00%, 17.50%, 18.00% and 18.50%). Pada 
penelitian ini dilakukan optimasi kitosan dengan variasi konsentrasi kitosan 16,00%, 
16,50%, 17,00%, 17,50%, 18,00% dan 18,50%. Each concentration will be observed 
how the effect of increasing concentrations of chitosan on ranitidine HCl floating tablet 
dissolution. Chitosan is expected to provide the properties of slow-release tablet dosage 
form at ranitidine HCl ideal, which fulfill the physical requirements of tablets and able 
to maintain a more stable drug release for a certain time. 
METHODOLOGY 
A. Equipments 
Equipments used in this study include the single punch printing machines, 
hardness tester, friability tester, dissolution tester, UV-Vis spectrophotometer, an 





measuring cup, volumetric flask, storey sieve, measuring pipette, granule flow tester, 
mortar, stamper, calipers and glass tools. 
 
B. Materials  
Ranitidine hydrochloride (Union Quimico Farmaceutica, S.A), chitosan 
(Biotech Surindo), Avicel pH 102, sodium bicarbonate, talc, magnesium stearate, HCl 
0,1 N, aquadest and alcohol 96%. 
 
C. Procedures 
1. Production Method of Ranitidine HCl Floating Tablets 
Table 1. Formula of Ranitidine HCl Floating Tablet 
Materials 
Total Material In Formula (mg) 
Function 
F1 F2 F3 F4 F5 F6 
Ranitidine HCl 150 150 150 150 150 150 
Active 
Substance 





125 125 125 125 125 125 
Source Bases 
MCC PH 102 25 25 25 25 25 25 Binder 
Magnesium 
Stearate 
5 5 5 5 5 5 
Lubricants 
Talc ad 500 500 500 500 500 500 Filler 
 
The initial step is to conduct pre-mixing process by mixing ranitidine HCl, 
matrix polymers (chitosan) and avicel pH 102, and then stir until homogeneous. And 
then add 96% alcohol until it forms a a mass which can be clenched. Sieved the moist 
mass using a mesh  number 8. Then dried at 50 ° C for 18 hours (Parrot 1971).  After 
drying, the granules sieved again using mesh number 16. The granules which obtained, 
added the external phase of sodium bicarbonate, magnesium stearate and talc as a base 
resource, lubricant and filler, then mixed until homogeneous. Then evaluate the 
granules.  
 The granules already evaluated then molded into tablets (500 mg) and then 






2. The Granule Evaluation of Ranitidine HCl Floating Tablet  
The granules evaluation of Ranitidine HCl floating tablet before compressed, 
include: flow time test, angle of repose test, compressibility test, and particle size 
distribution test. 
3. The Evaluation of Ranitidine HCl Floating Tablet  
The evaluation of Ranitidine HCl tablets, include: organoleptic test, size 
uniformity test, weight uniformity test, hardness test, friability test, swelling test, 
floating lag time test, the total floating time test, the assay test, and dissolution test. 
4. Preparation of Ranitidine HCl Standard Solution 
100.0 mg ranitidine HCl was weighed and added to 100.0 ml volumetric flask, 
then dissolved with 0.1N HCl until the mark boundaries, and we get a standard solution 
with a concentration of 1000 ug / ml. 
5. Determination of Ranitidine HCl Maximum Wavelength 
Pipetted from the standard solution as much as 1.0 ml and put 100.0 ml into a 
flask volumetric, 0.1 N HCl was added until the mark. Then the absorbance was 
measured using a spectrophotometer at a wavelength of 200-400 nm. It will get a 
maximum wavelength of Ranitidine HCl. 
6. Preparation of Calibration Curve Ranitidine HCl 
Made concentration series from standard solution (4, 6, 8, 10, and 12 ug / ml). 
Pipetted a standard solution put into a volumetric flask and then added a 100.0 ml 
solution of HCl 0.1 N to the mark. After that read the absorbance with using a 
spectrophotometer at a maximum wavelength of 227.60 nm, then made the plot 
between the concentration of Ranitidine HCl and absorption, it will obtain a regression 
line linear equation 
 
RESULT AND DISCUSSION 
1. The evaluation result of Ranitidine HCL 
The evaluation result of Ranitidine HCL consisting of the examination of 






Table 2. The evaluation result of Ranitidine HCL 
Evaluation Result 




2) Absorbance of UV Spectrum  
 
Crystalline powder white to pale yellow, practically 
odorless  
 
227,60 nm (HCl 0,1 N) 
 
2. Maximum Wavelength of Ranitidine HCl 
The maximum wavelength of ranitidine HCl determined at 200-400 nm using a 
Spectrophotometer Visibel. Determination of the maximum wavelength aimed to know 
the absorption can reach the maximum, thus increasing the absorption process of the 
solution to light. According to the Pharmacopoeia V edition, the maximum wavelength 
of ranitidine HCl is approximately 229 nm and 314 nm. The results obtained in the 
media 0.1N HCl solution shows maximum wavelength of 227.6 nm with the 
absorbance value of 0.6412. It concluded that the substance was ranitidine HCl and has 
a good quality of raw materials. This wavelength is used to create a calibration curve. 
 
 
Picture 1. Maximum Wavelenght of Ranitidine HCl 
 
3. Calibration Curve Of Ranitidine HCl 
In the evaluation results of calibration curve using the equation A = a.b.c, 





ppm). From a calibration curve can be made concentration of 4 ppm, 6 ppm, 8 ppm, 10 
ppm and 12 ppm in 0.1 N HCl solution is then measured with a spectrophotometer.  
The result has the value of the intercept (a) obtained is -2x10-4, while the 
intercept good value is 0. Regression values obtained is 0.9999. A good regression 
value is the correlation coefficient has the value 1. Based on the results of the calibration 
curve can be concluded that the law Lambet-Beer has been fulfilled and ranitidine HCl 
eligible to continue for assay test. 
 
Picture 2. Calibration Curve of Ranitidine HCl 
 
4. Evaluation of Granules 
Table 3. The Result of Granules Evaluation Ranitidine HCl Floating Tablet  
Parameter F1 F2 F3 F4 F5 F6 Requirement 
Flow time (sec) 7,72 8,32 8,82 8,91 9,18 9,27 
10 g/sec (Siregar dan 
Saleh 2010) 
Angle of repose (°) 33,41 34,21 31,36 34,21 34,21 31,36 25 - 40° (Agoes 2012) 
Compressibility (%) 3,99 2,00 4,33 5,00 4,00 4,00 
< 20% (Siregar dan 
Saleh 2010) 
Drying shrinkage (%) 2,45 3,76 2,86 2,77 3,28 4,05 3-5% (Voigt (1995) 
 
Flow time test results obtained showed that all formulas have a flow that 
suitable with the specified requirements at less than 10 seconds (Siregar, 2010). This is 
possibly due to the formula contains magnesium stearate which serves as a lubricant. 
Then test the angle of repose, which showed that the granules entire formula 
accordance with the requirements is 25-45⁰ (Agoes 2012). The more flat from the 





properties of the powder. If a granule has good flow properties will be obtained tablet 
that has a good weight uniformity. 
The test results granule compressibility formula 1 sampa 6 comply with the 
requirements ie <20% (Agoes 2012). This is influenced because the manufacture of 
tablets using wet granulation method, thus increasing the overall weight of the type of 
material and produce a mixture with good flow properties and homogeneous, and the 
presence of fillers and binders in the composition of the formula. The lower the 
compressibility obtained the better the flow properties, but if the higher value of its 
compressibility will make the tablet sink (hard float).  
Drying shrinkage test aimed at the preparation using wet granulation method 
because of water usage or other solvents as binder activators that should be evaluated. 
Data of formula 1 to 6 shows the drying shrinkage test results are good, because the 
percentage obtained moisture content below 10%. But in Formula 1, Formula 3 and 
Formula 4 does not fulfill the requirements set is 3-5% for the water content of the 
granules (Voigt 1995). This may be due to differences in the length of time the heating 
granules. The lower the water content can cause the tablet to be easily cracked and split 
into two parts, while the greater the water content can cause adhesion of granules on a 
punch.  
The result of the particle size distribution of all formula, showing that the 
granules much spread on the sieve mesh number 18, while the mesh number 24 to 60 
has decreased by degrees. In this test the granules with a larger size resulting in large 
numbers, this is because the characteristics of chitosan that can absorb water, so that 
the resulting granules have high humidity. The good graphic are graphic representations 
showing the results of granules spread percentation which restrained in small mesh and 
large mesh numbers must be balance. The results of the evaluation of particle 
distribution in the entire formula is not consistent with the theory. The size distribution 
of granules can be affected by several things, including granulation method, the amount 
of binder solution, a process of making granules, and equipment (Hadisoewignyo and 







Picture 3. Distribution of Particle Size 
5. The Result Of Evaluation Tablet 
Organoleptic evaluation aims to control the uniformity of tablets appearance, 
consumer acceptance, and monitor the right making process. Floating tablet which 
generated from the sixth formula has a pale yellow color, round shaped, bitter tasted, 
and has a rough surface texture 
Tablet weight uniformity test was conducted by examining the weight of 10 
tablets. The results of the test weight uniformity tablet from formula 1 to formula 6 are 
qualifies, because no two tablets that weighs deviates 5% of the tablet weight average 
and there is no one tablet which has a tablet weight deviation  10% of the tablet average 



















































2,50 1,9 1,9 1,7 2,6 1,8 
< 2 tablet that deviates from 
the 5% and 1 tablet should 
not be deviated from 10% 
(Departemen Kesehatan RI 
2014) 
Hardness 2,76 2,13 2,66 3,67 3,49 3,35 4-8 Kg/cm2 (Elhassan 2012) 
Friability 0,09 0,09 0,29 0,09 0,16 0,23 < 1% (Ben 2008) 
Diameter 
(cm) 
1,7927 1,7956 1,7958 1,7953 1,758 1,7949 
No less than 1 1/3 and not 
greater than 3x tablet 
thickness (Departemen 
Kesehatan RI 1979) 
Thickness 
(mm) 
2,6300 2,5850 2,6230 2,6120 2,5933 2,6060 - 
Swelling 
index (%) 
12,96 16,17 24,12 31,56 28,96 25,55 - 
Floating lag 
time (s) 
213 206 286 309 333 222 




07.46 07.48 07.30 12.45 08.30 08.05 




95,77 95,98 99,48 103,18 103,60 109,16 90-110 % (Depkes RI 2014) 
 
Hardness test results for 10 tablets in Table 4, it can be concluded that the tablet 
formula 1 to formula 6 does not fulfill the hardness requirements which already 
established as a tablet standard is 4-8 kg/cm2 (Elhassan 2012). This possibility caused 
by the low compression pressure and material properties which compressed. But the 
tablet hardness values that are beyond the required range does not indicate that a tablet 
has a poor quality. Hardness values of tablet less than 4 kg still acceptable on condition 
of fragility does not exceed the limit (Sulaiman 2007).  
Tablet friability test performed on a sample of 10 tablets. The test results 
showed that fragility tablet of formula 1 to 6 are fulfill the requirements because of its 
value below 1%. Therefore, it can be concluded that the tablets were tested had a good 
levels of compactness tablet, because the higher compactness of tablets, resulting the 





Tablet size uniformity test was conducted by measuring the diameter and 
thickness of the tablet. Data results in table 10 it can be seen that the entire tablet 
formula fulfill the requirements of  the size uniformity which established by the third 
edition Indonesian Pharmacopoeia, in which the tablet diameter should not be more 
than 3 times thicker and not less than 4/3 thickness. This occurs because of the amount 
of granules into the punch or die has the same mass and influenced by the good flow 
properties of granules. 
Swelling time test is the most important parameter in floating tablet dosage. 
Swelling time test viewed and counted starting at the time of the tablet entry into the 
medium and then swelling. The increasing concentration of chitosan can make the 
result of swelling tablet will be greater. But the results of swelling was highest in 
formulas 4 and 5 as chitosan can slow the formation of CO2, so the possibility of  drug 
release can be slowed from the other formula (Rosa et al. 1994). 
Floating lag time test influenced by the swelling power of the polymers used in 
the formula. The results of tests known that floating lag time from the sixth tablet 
formula fulfill the requirements that are in the range 25-600 seconds (0.4 to 6 minutes). 
This occurs because the CO2 gas can be formed quickly so the tablet can float in the 
medium with the time span which fulfill the requirements. 
Furthermore, the total time floating test is the time which the ranitidine takes to 
float in the stomach. Floating tablet caused by the formation of CO2 as a result of the 
neutralization reaction between NaHCO3 and HCl 0.1 N. When the tablet into the 
stomach, the gastric acid fluid will penetrates the pores of the matrix which consisting 
of gel polymer and react with alkaline of NaHCO3 resulting CO2. The gas was trapped 
in the hydrocolloid which formed and can not come out. That makes the tablet density 
decreases so it can float and last longer in the stomach. The evaluation result of the total 
floating time which fulfill the requirements only  formula 4 (12:45:45) to determine 
how long the tablet floats in the medium HCl 0,1N (Rosa et al. 1994). 
In the assay test of ranitidine HCl tablet from all formula, all of the formula 
fulfill the requirements established by the Indonesian Pharmacopoeia V edition that 





ranitidine HCl listed on the formula. But all of formula does not fulfill the requirements 
of homogeneity that is the coefficient of variation more than 6%.  
The main goal from the development of floating tablet dosage form is improves 
the bioavailability over an extended residence time in the stomach and extend 
preparation time by holding the drug release rate. Based on these goals, it can be 
concluded that the dissolution testing is an important parameter to examining the 
success from controlled release dosage of floating system. All of formula floating 
ranitidine HCl tablets, the dissolution test is only performed in the formula 4 and 5, 
because the results test in the swelling index of formula 4 and 5 that have a percentage 
of swelling tablet diameter greater than the other. It can be concluded that the larger of 
swelling potency of the tablet will make the percentage released of active substance in 
the tablet be increased.  
 
 
Picture 4. Dissolution Profile of Ranitidine HCl Floating Tablets 
 
Data dissolution of both formulas was obtained that the levels of ranitidine 
HCl were dissolved at minute 5, 10, 15, 30, 60, 120, 240, and 480 showed increased 
significantly with the different concentration, so there are differences between each 
tablet. The explanation of relationship between the concentration levels ratio of the 
polymeric matrix in the dissolution of ranitidine HCl can showed that chitosan can 
increase the release of the drug in controlled release dosage form and has resistance in 
























Based on this study, the use of chitosan as a matrix polymer in floating tablet 
can affect the physical characteristics of the tablet mass, swelling index, floating lag 
time, and total floating time. The optimum amount of chitosan as a polymer matrix for 
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